By Fineline Cube 
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received separate clinical trial approvals from the National Medical Products Administration (NMPA) for its two innovative drugs, SHR-3792 and HRS-9190. This marks a significant step forward in the development of novel therapies for advanced solid tumors and anesthesia-related applications.
SHR-3792: Novel Anti-Tumor Therapy
SHR-3792 is an in-house developed novel anti-tumor drug candidate designed to target advanced solid tumors. Pre-clinical animal models have demonstrated promising anti-tumor activity, with no similar product currently approved globally. This positions SHR-3792 as a potential first-in-class therapy, addressing a critical unmet need in oncology.
HRS-9190: Anesthesia and Muscle Relaxation
HRS-9190 is a Category 1 drug intended for use during general anesthesia induction for tracheal intubation and the maintenance of intraoperative skeletal muscle relaxation. The drug’s approval for clinical trials highlights Hengrui’s expanding portfolio in anesthesia and critical care, further solidifying its position as a leader in innovative pharmaceutical development.-Fineline Info & Tech